The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Partnering on Personnel: Strategies for Success
Kaiser Permanente Opens First Two Medical Offices in Northern Nevada
Acadia Healthcare Reports Data Breach
Site Selection Mistakes: What Not To Do
High-Performance EFCO Systems Shape MUSC's New Black River Medical Center